Centessa Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Centessa Pharmaceuticals's earnings have been declining at an average annual rate of -5.1%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 157.3% per year.
Key information
-5.1%
Earnings growth rate
24.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 157.3% |
| Return on equity | -64.3% |
| Net Margin | -2,019.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Centessa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 7 | -138 | 51 | 114 |
| 31 Dec 23 | 7 | -151 | 54 | 124 |
| 30 Sep 23 | 0 | -157 | 55 | 120 |
| 30 Jun 23 | 0 | -173 | 55 | 128 |
| 31 Mar 23 | 0 | -212 | 57 | 148 |
| 31 Dec 22 | 0 | -216 | 55 | 155 |
| 30 Sep 22 | 0 | -234 | 54 | 169 |
| 30 Jun 22 | 0 | -220 | 55 | 158 |
| 31 Mar 22 | 0 | -197 | 52 | 122 |
| 31 Dec 21 | 0 | -381 | 43 | 96 |
| 30 Sep 21 | 0 | -324 | 30 | 57 |
| 30 Jun 21 | 0 | -286 | 18 | 34 |
| 31 Mar 21 | 0 | -246 | 6 | 17 |
| 31 Dec 20 | 0 | -11 | 1 | 9 |
Quality Earnings: 260 is currently unprofitable.
Growing Profit Margin: 260 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 260 is unprofitable, and losses have increased over the past 5 years at a rate of 5.1% per year.
Accelerating Growth: Unable to compare 260's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 260 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 260 has a negative Return on Equity (-64.33%), as it is currently unprofitable.